DLGAP5 promotes lung adenocarcinoma growth via upregulating PLK1 and serves as a therapeutic target

• Published in: Journal of translational medicine Vol. 22; no. 1; pp. 209 - 20
• Main Authors: Chen, Maojian, Zhang, Shaoping, Wang, Fan, He, Junyi, Jiang, Wei, Zhang, Li
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 27.02.2024; BioMed Central; BMC
• Subjects: Adenocarcinoma; Analysis; Apoptosis; AT9283; Bioinformatics; Biological markers; Bisphenol A; Cancer therapies; Care and treatment; Cell culture; Cell cycle; Cell growth; Cell proliferation; Development and progression; DLGAP5; Drug development; Gene expression; Genetic aspects; Genomes; Genomics; Health aspects; Immune checkpoint inhibitors; Immunosuppressive agents; Immunotherapy; Infiltration; Kinases; Ligands; Liver cancer; LUAD; Lung cancer; Medical prognosis; Metastases; Mutation; Online data bases; Ovarian cancer; PLK1; Polo-like kinase 1; Prognosis; Protein expression; Proteins; Simulation; Survival analysis; Therapeutic targets; Tumorigenesis; China; United States > US; AT9283; DLGAP5; PLK1; LUAD
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/s12967-024-04910-8

Human discs large-associated protein 5 (DLGAP5) is reported to play a pivotal role in regulating the cell cycle and implicate in tumorigenesis and progression of various cancers. Our current research endeavored to explore the prognostic value, immune implication, biological function and targeting strategy of DLGAP5 in LUAD through approaches including bioinformatics, network pharmacology analysis and experimental study. Multiple databases, including TCGA, GEO, CPTAC and Human Protein Atlas, were utilized to explore the expression and clinical significance of DLGAP5 in LUAD. The genetic alterations of DLGAP5 were assessed through cBioPortal and COSMIC databases. The relationship between DLGAP5 expression and genetic abnormalities of driver genes in LUAD was analyzed through TIMER2.0 database. CancerSEA database was utilized to explore the function of DLGAP5 in 14 different states in LUAD at single-cell resolution. GDSC database was utilized to analyze the impact of DLGAP5 on IC50 of frequently-used anti-LUAD drugs. CIBERSORT method and TIMER2.0 database was utilized to explore the relationship between DLGAP5 and tumor immune infiltration. Network pharmacology was applied to screen potential DLGAP5 inhibitor. In vitro and in vivo experiments were utilized to evaluate biological function and downstream targets of DLGAP5, and the effect of screened DLGAP5 inhibitor on LUAD growth. High DLGAP5 expression was commonly observed in LUAD and associated with mutation of major driver genes, poor prognosis, high IC50 values of frequently-used anti-LUAD drugs, increasing immune infiltration and elevated immune checkpoint blockade-related genes in LUAD. PLK1 was revealed as a potential DLGAP5 downstream target in LUAD. DLGAP5 overexpression or knockdown significantly promoted or inhibited LUAD cell proliferation and PLK1 expression. PLK1 overexpression well rescued DLGAP5 knockdown-induced cell proliferation inhibition, or vice versa. Furthermore, by virtual screening of an investigational drug library from the DrugBank database, AT9283 was screened and identified as a novel DLGAP5 inhibitor. AT9283 effectively suppressed growth of LUAD cells both in vitro and in vivo. DLGAP5 overexpression significantly reversed AT9283-induced proliferation inhibition. Moreover, AT9283 significantly suppressed DLGAP5 and PLK1 expression, while DLGAP5 overexpression significantly reversed AT9283-induced PLK1 suppression. Our research has demonstrated that DLGAP5 is upregulated in LUAD and exhibits a strong correlation with unfavorable prognosis. Furthermore, DLGAP5 assumes a significant function in the regulation of tumor immunity and treatment outcome of immune checkpoint inhibitors. Of note, we found that DLGAP5 promotes cell proliferation of LUAD via upregulating PLK1. Targeting DLGAP5 by AT9283, our newly identified DLGAP5 inhibitor, suppresses LUAD growth. DLGAP5 may become a promising prognostic biomarker and therapeutic target for patients with LUAD.